Amfexa is a brand name for lisdexamfetamine dimesylate, a prescription medication primarily used to treat Attention Deficit Hyperactivity Disorder (ADHD) in children (aged 6+), adolescents, and adults. It’s also approved in some regions for binge eating disorder (BED).

Key Facts

• Drug Class: Central nervous system (CNS) stimulant; a prodrug of dextroamphetamine (inactive until metabolized in the body).
• How It Works: Increases levels of dopamine and norepinephrine in the brain, improving focus, attention, and impulse control.
• Brand Equivalents: Known as Vyvanse in the US, Canada, and elsewhere; Amfexa is the EU/UK branding by Takeda.

Evidence & Sources: Approved by EMA (EU) in 2012 for ADHD; FDA (as Vyvanse) in 2007. Clinical trials (e.g., Biederman et al., 2007 in J Am Acad Child Adolesc Psychiatry) show 60-70% response rate in ADHD vs. placebo. Full prescribing info: EMA Amfexa Summary or FDA Vyvanse Label.

Warning: This is general info—consult a doctor for personal advice, as it’s a controlled substance with risks. Not medical advice. If you’re asking for personal use, see a healthcare provider.